How EBV hijacks your cells, study by study
Last reviewed November 15, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
Most viruses are a smash and grab. They break into cells, copy themselves, burst out and get cleared in a week or two. Epstein-Barr virus does something else: it moves in permanently, using your own cells' machinery and raw materials to build every copy of itself, then goes silent inside the very immune cells whose job is to spot invaders.
Here is each step of that process and what the evidence behind it actually is. For who carries it and how it spreads, see our page on the virus almost everyone has.
Related pages: Epstein-Barr virus (EBV) infection · Mononucleosis (mono)
The bottom line
- EBV is a double-stranded DNA herpesvirus. It infects throat lining cells and B cells, the white blood cells that make antibodies.
- It can switch between several gene programs. One drives infected B cells to multiply; another shuts nearly everything off so the virus is invisible.
- It settles permanently in memory B cells and is never cleared from the body.
- No drug removes latent EBV. Antivirals act only on the active, copying form.
- Exactly what triggers the switch out of dormancy in everyday life.
- Why a very small number of people develop EBV-driven cancer while almost everyone else carries the same virus without harm.
The studies, in order
- 1. What it is (Established virology)
- 2. Getting in (Decades of cell biology work)
- 3. The hijack (Thorley-Lawson and many others)
- 4. Going dark (Babcock, Thorley-Lawson and colleagues, 2000 onward)
- 5. Waking up (Lab and human studies)
- 6. When it goes wrong (International Agency for Research on Cancer and others)
- 7. What can be done (Vaccine and cell therapy programs)
What the evidence labels mean
A herpesvirus built for permanent residence
What they did
EBV, also called human herpesvirus 4, carries its genes as double-stranded DNA inside a protein shell wrapped in a fatty envelope.
What they found
- Herpesviruses as a family are built to stay for life rather than be cleared.
- EBV's genome is about 170,000 letters long and codes for roughly 80 proteins, but it only uses a handful at a time.
- More than 90% of adults worldwide carry it.
What it means
The lifelong part isn't a failure of your immune system. It is the virus's normal strategy, and it is why 'getting rid of EBV' isn't something medicine can currently offer.
What it can't tell us
- Carrying EBV is the normal human condition, so finding it in a tissue sample doesn't by itself prove it caused anything.
Read it yourself
- CDC: About Epstein-Barr virusGovernment
- Dunmire 2018, Journal of Clinical Virology: Primary EBV infection (PubMed)PubMed
Next: Getting in
Two doors: the throat lining, then the B cells
What they did
EBV arrives in saliva and meets the tissue at the back of the throat and the tonsils.
What they found
- It first infects epithelial cells, the lining cells of the throat, where it makes new copies.
- It then infects B cells, latching on using a surface protein called CD21 along with other receptors, and is drawn inside.
- The virus carries separate envelope proteins for each door. Entry into B cells and entry into lining cells use different combinations.
What it means
Those entry proteins are exactly what the EBV vaccines now in trials are aimed at: block the doors and the virus can't get in.
What it can't tell us
- Whether lining cells or B cells are infected first in real human infection is still argued; it may go both ways.
Read it yourself
- Dunmire 2018, Journal of Clinical Virology: Primary EBV infection (PubMed)PubMed
- European Pharmaceutical Review: EBV mRNA vaccine targets four envelope proteinsNews
Next: The hijack
The growth program: nine viral proteins take the wheel
What they did
Once inside a B cell, EBV switches on its fullest set of genes, known as latency III or the growth program.
What they found
- Nine viral proteins, six nuclear antigens (the EBNAs) and three membrane proteins (the LMPs), are produced at once.
- They imitate the signals a B cell normally gets from the immune system, so the cell behaves as if it has been told to multiply.
- One of them, LMP1, copies a permanently switched-on version of a receptor the cell uses to decide whether to live or die.
- In a dish, this turns ordinary human B cells into cell lines that divide indefinitely.
What it means
This is the hijack in the strict sense. The virus doesn't just borrow raw materials, it takes over the cell's decision-making so the cell builds and maintains virus-carrying copies of itself.
What it can't tell us
- Cells running this full program are loudly visible to the immune system, which is why they are cleared in healthy people and only persist when immunity is suppressed.
Read it yourself
- Review: EBV latency programs and B-cell immortalizationJournal
- Thorley-Lawson 2013: The pathogenesis of EBV persistent infectionJournal
Next: Going dark
The virus shuts almost every gene off and disappears
What they did
Researchers sorted B cells from human blood and tonsils and tested which viral genes were switched on in each type.
What they found
- The virus's long-term home is the resting memory B cell, the kind of cell your body keeps for decades to remember past infections.
- In those cells the viral DNA sits as a closed ring, called an episome, and essentially no viral proteins are made. This is called latency 0.
- When the cell divides, the virus briefly makes one protein, EBNA1, purely to copy its ring along with the cell's own DNA.
- To get there, the infected cell passes through the germinal center, the normal training ground where B cells mature, using the body's own development pathway.
What it means
Making no proteins means there is nothing for killer T cells to see. That is why EBV survives for life in a person with a perfectly good immune system, and why no vaccine or drug can reach it once it is there.
What it can't tell us
- An alternative model holds that EBV directly infects memory B cells without the germinal center detour. The question isn't fully closed.
Read it yourself
Next: Waking up
Reactivation: a switch flips and copies get made again
What they did
Every so often a latent cell switches back into the productive (lytic) mode, driven by a master switch gene known as BZLF1.
What they found
- The virus makes full copies, which are shed into saliva. Over 90% of healthy carriers shed EBV in their saliva from time to time.
- In healthy people this happens without symptoms and is pushed back down by killer T cells.
- In lab cells, steroid hormones can flip that switch, and the pattern of the hormone over time seems to matter more than the plain level.
What it means
This is why EBV spreads so easily. The main source isn't sick people, it's healthy carriers going about their lives.
What it can't tell us
- A lab test showing 'reactivation' in a healthy person is common and by itself doesn't explain symptoms.
- What triggers reactivation in ordinary daily life is still not well mapped.
Read it yourself
- Review: stress hormones and EBV reactivationJournal
- OwieClear: How your body keeps EBV locked downOwieClear
Next: When it goes wrong
The same tricks, in the wrong cell, become cancer
What they did
Researchers estimated how many cancers worldwide can be attributed to EBV.
What they found
- EBV was linked to roughly 120,000 to 160,000 new cancer cases a year in the two IARC estimates, and higher in analyses that count more cancer types.
- It is found in about 85% of nasopharyngeal carcinoma, around half of Hodgkin lymphoma, and most Burkitt lymphoma cases.
- Burkitt lymphoma clusters in regions with heavy malaria, which appears to weaken the immune control of EBV.
What it means
The growth program that makes a B cell divide is a cancer-driving program if the brakes come off. Almost everyone carries EBV, so what differs in these cases is the brakes, not the virus.
What it can't tell us
- EBV is almost never the only cause. Other genetic changes, malaria, or immune suppression are usually needed too.
- The global totals vary a lot depending on which cancers are counted.
Read it yourself
Next: What can be done
Nothing clears it, but the entry doors and the control system can be targeted
What they did
Two approaches are being tested: stopping infection in the first place, and rebuilding immune control in people who have lost it.
What they found
- Moderna's mRNA-1189 vaccine carries instructions for four EBV envelope proteins and aims to prevent mono. Early trials reported it was tolerated and produced an immune response; a larger trial has been planned.
- A second candidate, mRNA-1195, targets EBV-driven disease in transplant patients and MS.
- For people whose immune control has failed after a transplant, donor-derived EBV-specific T cells are used as a treatment.
What it means
Prevention looks more realistic than cure. Once the virus is in your memory B cells, there is currently no way to evict it.
What it can't tell us
- No EBV vaccine is approved. Trial results so far are about immune response, not proof of preventing disease.
- Vaccine designers have to avoid using EBNA1, since antibodies to it are the ones implicated in MS.